Published in J Comput Aided Mol Des on November 01, 2009
Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta (2010) 1.53
The resurgence of A2B adenosine receptor signaling. Biochim Biophys Acta (2010) 1.23
Simulation and comparative analysis of binding modes of nucleoside and non-nucleoside agonists at the A2B adenosine receptor. In Silico Pharmacol (2013) 0.79
Role of extracellular cysteine residues in the adenosine A2A receptor. Purinergic Signal (2016) 0.78
Structural determinants of the alpha2 adrenoceptor subtype selectivity. J Mol Graph Model (2011) 0.78
Three "hotspots" important for adenosine A(2B) receptor activation: a mutational analysis of transmembrane domains 4 and 5 and the second extracellular loop. Purinergic Signal (2011) 0.77
Characterization of adenosine receptor in its native environment: insights from molecular dynamics simulations of palmitoylated/glycosylated, membrane-integrated human A(2B) adenosine receptor. J Mol Model (2012) 0.77
Comparison analysis of primary ligand-binding sites in seven-helix membrane proteins. Biopolymers (2011) 0.76
A Novel Method for Screening Adenosine Receptor Specific Agonists for Use in Adenosine Drug Development. Sci Rep (2017) 0.75
Stimulation of Adenosine A2B Receptor Inhibits Endothelin-1-Induced Cardiac Fibroblast Proliferation and α-Smooth Muscle Actin Synthesis Through the cAMP/Epac/PI3K/Akt-Signaling Pathway. Front Pharmacol (2017) 0.75
The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools. Nucleic Acids Res (1997) 175.36
The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. Nucleic Acids Res (2000) 67.44
Crystal structure of rhodopsin: A G protein-coupled receptor. Science (2000) 28.60
High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science (2007) 20.32
How many drug targets are there? Nat Rev Drug Discov (2006) 14.22
GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science (2007) 11.74
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science (2008) 11.74
The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol Pharmacol (2003) 9.99
International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev (2001) 9.90
Recognition of errors in three-dimensional structures of proteins. Proteins (1993) 9.38
A graph-theory algorithm for rapid protein side-chain prediction. Protein Sci (2003) 9.25
Stereochemical quality of protein structure coordinates. Proteins (1992) 9.18
The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. J Mol Biol (2004) 7.38
A fast flexible docking method using an incremental construction algorithm. J Mol Biol (1996) 7.33
Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature (2008) 7.20
Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J (1999) 6.25
Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov (2008) 6.18
[3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. J Pharmacol Exp Ther (1989) 4.18
Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation (2007) 3.65
The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med (2008) 2.43
Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol (1998) 2.43
Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci (1997) 2.09
Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J Biol Chem (1995) 1.92
Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. J Med Chem (2000) 1.92
On the accuracy of homology modeling and sequence alignment methods applied to membrane proteins. Biophys J (2006) 1.79
Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. Mol Pharmacol (1996) 1.54
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J Med Chem (1997) 1.51
Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors. J Med Chem (2000) 1.44
Comparison of CGS 15943, ZM 241385 and SCH 58261 as antagonists at human adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol (1999) 1.35
Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition. Mol Pharmacol (1996) 1.33
Screening drug-like compounds by docking to homology models: a systematic study. J Chem Inf Model (2006) 1.23
Ranking ligand binding affinities with avidin: a molecular dynamics-based interaction energy study. Proteins (1999) 1.16
Site-directed mutagenesis studies of human A(2A) adenosine receptors: involvement of glu(13) and his(278) in ligand binding and sodium modulation. Biochem Pharmacol (2000) 1.11
2-Substituted adenosine derivatives: affinity and efficacy at four subtypes of human adenosine receptors. Biochem Pharmacol (2004) 1.11
Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine] in rodent models of movement disorders and depression. J Pharmacol Exp Ther (2009) 1.09
The Quintiles Prize Lecture 2004. The identification of the adenosine A2B receptor as a novel therapeutic target in asthma. Br J Pharmacol (2005) 1.08
Multiple automatic base selection: protein-ligand docking based on incremental construction without manual intervention. J Comput Aided Mol Des (1997) 1.02
Homology model-based virtual screening for GPCR ligands using docking and target-biased scoring. J Chem Inf Model (2008) 1.01
Medicinal chemistry and pharmacology of A2B adenosine receptors. Curr Top Med Chem (2003) 0.99
Adenosine receptor ligands-recent developments part I. Agonists. Curr Med Chem (2000) 0.99
Evaluation of the utility of homology models in high throughput docking. J Mol Model (2007) 0.98
Molecular dynamics simulations of bovine rhodopsin: influence of protonation states and different membrane-mimicking environments. J Mol Model (2005) 0.96
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem (2002) 0.95
Structure selection for protein kinase docking and virtual screening: homology models or crystal structures? Curr Protein Pept Sci (2006) 0.94
Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists. J Med Chem (2000) 0.94
Computer aided comparative analysis of the binding modes of the adenosine receptor agonists for all known subtypes of adenosine receptors. J Mol Graph Model (2006) 0.93
Why are A(2B) receptors low-affinity adenosine receptors? Mutation of Asn273 to Tyr increases affinity of human A(2B) receptor for 2-(1-Hexynyl)adenosine. Mol Pharmacol (2000) 0.92
Generation of a homology model of the human histamine H(3) receptor for ligand docking and pharmacophore-based screening. J Comput Aided Mol Des (2007) 0.92
Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists. J Med Chem (2004) 0.91
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. J Med Chem (2002) 0.89
Discovery and characterization of 4'-(2-furyl)-N-pyridin-3-yl-4,5'-bipyrimidin-2'-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist. J Med Chem (2007) 0.86
Random mutagenesis of the human adenosine A2B receptor followed by growth selection in yeast. Identification of constitutively active and gain of function mutations. Mol Pharmacol (2004) 0.86
[3H]OSIP339391, a selective, novel, and high affinity antagonist radioligand for adenosine A2B receptors. Biochem Pharmacol (2004) 0.86
Site-directed mutagenesis of the human adenosine A2A receptor. Critical involvement of Glu13 in agonist recognition. Eur J Pharmacol (1996) 0.84
A new synthesis of sulfonamides by aminolysis of p-nitrophenylsulfonates yielding potent and selective adenosine A2B receptor antagonists. J Med Chem (2006) 0.81
Molecular modeling and molecular dynamics simulation of the human A2B adenosine receptor. The study of the possible binding modes of the A2B receptor antagonists. J Med Chem (2005) 0.76
KW-6002 (Kyowa Hakko Kogyo). Curr Opin Investig Drugs (2001) 0.76
Statistical sequence analyses of G-protein-coupled receptors: structural and functional characteristics viewed with periodicities of entropy, hydrophobicity, and volume. Proteins (2004) 0.76
Synthesis and receptor affinity of polysubstituted adenosines. Nucleosides Nucleotides (1999) 0.75
Biochemistry of transmembrane signaling mediated by trimeric G proteins. Physiol Res (2004) 0.75
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev (2011) 4.16
Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. Sci Transl Med (2012) 2.46
CD39/ectonucleoside triphosphate diphosphohydrolase 1 provides myocardial protection during cardiac ischemia/reperfusion injury. Circulation (2007) 2.09
Contribution of E-NTPDase1 (CD39) to renal protection from ischemia-reperfusion injury. FASEB J (2007) 1.84
Decoding signaling and function of the orphan G protein-coupled receptor GPR17 with a small-molecule agonist. Sci Signal (2013) 1.71
CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology (2010) 1.69
P2 receptors activated by uracil nucleotides--an update. Curr Med Chem (2006) 1.62
Adenosine receptor antagonists including caffeine alter fetal brain development in mice. Sci Transl Med (2013) 1.46
Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. J Biol Chem (2002) 1.44
Involvement of adenosine A1 and A2A receptors in the motor effects of caffeine after its acute and chronic administration. Neuropsychopharmacology (2003) 1.41
Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs (2003) 1.39
Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol (2008) 1.24
Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis. Neuropharmacology (2008) 1.20
Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem (2006) 1.17
Synthesis of alkyl- and aryl-amino-substituted anthraquinone derivatives by microwave-assisted copper(0)-catalyzed Ullmann coupling reactions. Nat Protoc (2010) 1.16
Rapid and efficient microwave-assisted copper(0)-catalyzed ullmann coupling reaction: general access to anilinoanthraquinone derivatives. Org Lett (2007) 1.15
Recent developments in adenosine A2A receptor ligands. Handb Exp Pharmacol (2009) 1.15
Dopaminergic modulation of effort-related choice behavior as assessed by a progressive ratio chow feeding choice task: pharmacological studies and the role of individual differences. PLoS One (2012) 1.11
Role of central and peripheral adenosine receptors in the cardiovascular responses to intraperitoneal injections of adenosine A1 and A2A subtype receptor agonists. Br J Pharmacol (2005) 1.10
Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease. Pharmacol Ther (2011) 1.09
1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. J Med Chem (2009) 1.07
Adenosine A(2A) receptor antagonism reverses the effects of dopamine receptor antagonism on instrumental output and effort-related choice in the rat: implications for studies of psychomotor slowing. Psychopharmacology (Berl) (2006) 1.07
Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A(1) adenosine receptors. J Nat Prod (2002) 1.06
Antinociceptive effects of novel A2B adenosine receptor antagonists. J Pharmacol Exp Ther (2003) 1.05
Multigram-scale syntheses, stability, and photoreactions of A2A adenosine receptor antagonists with 8-styrylxanthine structure: potential drugs for Parkinson's disease. J Org Chem (2004) 1.03
Involvement of adenosine A1 receptors in the discriminative-stimulus effects of caffeine in rats. Psychopharmacology (Berl) (2005) 1.03
A capillary electrophoresis method for the characterization of ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) and the analysis of inhibitors by in-capillary enzymatic microreaction. Purinergic Signal (2005) 1.01
Allosteric modulators of rhodopsin-like G protein-coupled receptors: opportunities in drug development. Pharmacol Ther (2012) 1.00
Imidazo[2,1-b]thiazepines: synthesis, structure and evaluation of benzodiazepine receptor binding. Eur J Med Chem (2004) 0.98
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling. J Med Chem (2009) 0.98
Interaction of new, very potent non-nucleotide antagonists with Arg256 of the human platelet P2Y12 receptor. J Pharmacol Exp Ther (2009) 0.97
Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci Lett (2002) 0.97
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem (2002) 0.95
The adenosine A2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists. Psychopharmacology (Berl) (2008) 0.95
High-affinity, non-nucleotide-derived competitive antagonists of platelet P2Y12 receptors. J Med Chem (2009) 0.95
Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. Curr Top Med Chem (2006) 0.95
Differential allosteric modulation by amiloride analogues of agonist and antagonist binding at A(1) and A(3) adenosine receptors. Biochem Pharmacol (2003) 0.95
The adenosine A2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure. Psychopharmacology (Berl) (2009) 0.94
Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability. J Med Chem (2004) 0.93
A detailed behavioral analysis of the acute motor effects of caffeine in the rat: involvement of adenosine A1 and A2A receptors. Psychopharmacology (Berl) (2005) 0.93
Reinforcing and neurochemical effects of cannabinoid CB1 receptor agonists, but not cocaine, are altered by an adenosine A2A receptor antagonist. Addict Biol (2010) 0.92
Synthesis and preliminary evaluation of [3H]PSB-0413, a selective antagonist radioligand for platelet P2Y12 receptors. Bioorg Med Chem Lett (2005) 0.92
Ecto-ATPase inhibition: ATP and adenosine release under physiological and ischemic in vivo conditions in the rat striatum. Exp Neurol (2011) 0.92
N-substituted phenoxazine and acridone derivatives: structure-activity relationships of potent P2X4 receptor antagonists. J Med Chem (2012) 0.92
Nucleoside-5'-monophosphates as prodrugs of adenosine A2A receptor agonists activated by ecto-5'-nucleotidase. J Med Chem (2009) 0.91
Improving potency, selectivity, and water solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones. ChemMedChem (2006) 0.91
Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg Med Chem (2010) 0.91
Ecto-5'-nucleotidase (CD73)-mediated formation of adenosine is critical for the striatal adenosine A2A receptor functions. J Neurosci (2013) 0.91
GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A2B receptor. FASEB J (2010) 0.91
Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats. Synapse (2003) 0.91
P2Y₂ and Gq/G₁₁ control blood pressure by mediating endothelial mechanotransduction. J Clin Invest (2015) 0.91
Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorg Med Chem Lett (2007) 0.90
Adenosine regulates CD8 T-cell priming by inhibition of membrane-proximal T-cell receptor signalling. Immunology (2009) 0.90
Mass spectrometric identification of modified urinary nucleosides used as potential biomedical markers by LC-ITMS coupling. Anal Bioanal Chem (2005) 0.89
The second extracellular loop of GPCRs determines subtype-selectivity and controls efficacy as evidenced by loop exchange study at A2 adenosine receptors. Biochem Pharmacol (2013) 0.89
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists. J Med Chem (2002) 0.89
Structure-activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family. J Med Chem (2009) 0.88
Adenosine A2A receptor blockade prevents memory dysfunction caused by beta-amyloid peptides but not by scopolamine or MK-801. Exp Neurol (2007) 0.88
Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold. J Med Chem (2013) 0.88
Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem (2010) 0.88
Cardiac myocyte-secreted cAMP exerts paracrine action via adenosine receptor activation. J Clin Invest (2014) 0.87
Extracellular NAD(+) induces a rise in [Ca(2+)](i) in activated human monocytes via engagement of P2Y(1) and P2Y(11) receptors. Cell Calcium (2009) 0.87
Interaction of valerian extracts of different polarity with adenosine receptors: identification of isovaltrate as an inverse agonist at A1 receptors. Biochem Pharmacol (2006) 0.87
Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors. J Med Chem (2011) 0.87
Enabling role of adenosine A1 receptors in adenosine A2A receptor-mediated striatal expression of c-fos. Eur J Neurosci (2003) 0.87
Crystal structure of the human ecto-5'-nucleotidase (CD73): insights into the regulation of purinergic signaling. Structure (2012) 0.87
Dopamine/adenosine interactions related to locomotion and tremor in animal models: possible relevance to parkinsonism. Parkinsonism Relat Disord (2008) 0.87
Effort-related motivational effects of the pro-inflammatory cytokine interleukin 1-beta: studies with the concurrent fixed ratio 5/ chow feeding choice task. Psychopharmacology (Berl) (2013) 0.87
Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5'-carboxamide. J Med Chem (2008) 0.86
Caffeine and an adenosine A(2A) receptor antagonist prevent memory impairment and synaptotoxicity in adult rats triggered by a convulsive episode in early life. J Neurochem (2009) 0.86
Structure-activity relationships of anthraquinone derivatives derived from bromaminic acid as inhibitors of ectonucleoside triphosphate diphosphohydrolases (E-NTPDases). Purinergic Signal (2008) 0.86
The map kinase ERK regulates renal activity of cyclin-dependent kinase 2 in experimental glomerulonephritis. Nephrol Dial Transplant (2007) 0.86
Enzymatic properties of an ecto-nucleoside triphosphate diphosphohydrolase from Legionella pneumophila: substrate specificity and requirement for virulence. J Biol Chem (2008) 0.85
Discovery of potent competitive antagonists and positive modulators of the P2X2 receptor. J Med Chem (2011) 0.85
Cloning and functional expression of a novel Gi protein-coupled receptor for adenine from mouse brain. Mol Pharmacol (2007) 0.85
The platelet P2Y(12) receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [(3)H]PSB-0413. Purinergic Signal (2012) 0.85
Role of P2 purinergic receptors in synaptic transmission under normoxic and ischaemic conditions in the CA1 region of rat hippocampal slices. Purinergic Signal (2007) 0.85
Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid. J Chem Inf Model (2007) 0.84
Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists. Bioorg Med Chem (2009) 0.84
Adenosine receptor subtype-selective antagonists in inflammation and hyperalgesia. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.84
Synthesis of uracil nucleotide analogs with a modified, acyclic ribose moiety as P2Y(2) receptor antagonists. Bioorg Med Chem (2009) 0.84
The four cysteine residues in the second extracellular loop of the human adenosine A2B receptor: role in ligand binding and receptor function. Biochem Pharmacol (2011) 0.83
Interactions between adenosine and dopamine receptor antagonists with different selectivity profiles: Effects on locomotor activity. Behav Brain Res (2010) 0.83
7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists. J Med Chem (2012) 0.83
Nucleoside/nucleobase transporters: drug targets of the future? Future Med Chem (2009) 0.83
Evidence for the functional expression and pharmacological characterization of adenine receptors in native cells and tissues. Mol Pharmacol (2004) 0.83
Stimulant effects of adenosine antagonists on operant behavior: differential actions of selective A2A and A1 antagonists. Psychopharmacology (Berl) (2011) 0.83
Selectivity is species-dependent: Characterization of standard agonists and antagonists at human, rat, and mouse adenosine receptors. Purinergic Signal (2015) 0.83
Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression. J Neurosci (2013) 0.82
Cellular localization of adenine receptors in the rat kidney and their functional significance in the inner medullary collecting duct. Am J Physiol Renal Physiol (2013) 0.82
[(3)H]Adenine is a suitable radioligand for the labeling of G protein-coupled adenine receptors but shows high affinity to bacterial contaminations in buffer solutions. Purinergic Signal (2007) 0.82
The novel adenosine A(2A) antagonist prodrug MSX-4 is effective in animal models related to motivational and motor functions. Pharmacol Biochem Behav (2012) 0.82
Characterization of human and rodent native and recombinant adenosine A(2B) receptors by radioligand binding studies. Purinergic Signal (2006) 0.82